FDA black box warning on the use of 80 mg simvastatin

Template:Hypercholesterolemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Associate Editor(s)-In-Chief: Kashish Goel, M.D.

Overview

Simvastatin 80 mg is the highest approved dose for this drug and it is estimated that approximately 2.1 million patients in the U.S. were prescribed this dose in the year 2010. In March 2010, FDA revised the simvastatin label and recommended that patients of Chinese descent should not receive simvastatin 80 mg with cholesterol-modifying doses of niacin-containing product. This review was based on the interim results of Heart Protection Study. On 8th June 2011, FDA added another black box warning to the use of high dose simvastatin. Based on the review of randomized clinical trial, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH), FDA recommended limiting the use of high-dose simvastatin. Following recommendations were given:

• Simvastatin 80 mg should not be started in new patients, including those who are taking lower doses.
• This dose should be used only in those who have taken this medication for more than 12 months without any evidence of myopathy.
• New contraindications and dose limitations added to the label for use with other medications.